Arcus Biosciences: Funding, Investors & Team (Sep 2026)
Arcus Biosciences is a biopharmaceutical company specializing in oncology, dedicated to discovering, developing, and selling innovative cancer treatments. The company focuses on using new insights in immunology to create new therapies for cancer. Arcus has several molecules in various stages of clinical development, including Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in clinical trials for multiple types of cancer. They also have AB680, the first small-molecule CD73 inhibitor in clinical development for pancreatic cancer treatment. Additionally, they are working on Domvanalimab (AB154), an anti-TIGIT monoclonal antibody, and AB308, an anti-TIGIT antibody, both being investigated for different types of cancer. Zimberelimab (AB122), their anti-PD-1 monoclonal antibody, is being explored in combination regimens. The company was founded in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
Arcus Biosciences has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Arcus Biosciences Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Arcus Biosciences Funding Rounds
Arcus Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Arcus Biosciences Funding Compared to Other Biotechnology Startups
Arcus Biosciences' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Arcus Biosciences in Biotechnology and Hayward
Companies Similar to Arcus Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Arcus Biosciences Funding FAQs
What does Arcus Biosciences do?
Arcus Biosciences is a biopharmaceutical company specializing in oncology, dedicated to discovering, developing, and selling innovative cancer treatments. The company focuses on using new insights in immunology to create new therapies for cancer. Arcus has several molecules in various stages of clinical development, including Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in clinical trials for multiple types of cancer. They also have AB680, the first small-molecule CD73 inhibitor in clinical development for pancreatic cancer treatment. Additionally, they are working on Domvanalimab (AB154), an anti-TIGIT monoclonal antibody, and AB308, an anti-TIGIT antibody, both being investigated for different types of cancer. Zimberelimab (AB122), their anti-PD-1 monoclonal antibody, is being explored in combination regimens. The company was founded in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
How much funding has Arcus Biosciences raised?
Arcus Biosciences has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2025.
When did Arcus Biosciences last raise funding?
Arcus Biosciences' most recent funding round on record is an undisclosed round of $150M, announced in Feb 2025.
Who founded Arcus Biosciences?
FundedIQ lists Terry Rosen (Founder) at Arcus Biosciences.
Where is Arcus Biosciences headquartered?
Arcus Biosciences is based in Hayward, California, United States.
How many employees does Arcus Biosciences have?
Arcus Biosciences is in the 101-250 employee band.
How does Arcus Biosciences' funding compare to other Biotechnology startups?
Arcus Biosciences' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Arcus Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Arcus Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.